Administration of antiretroviral (ARV) drugs before potential HIV exposure in order to reduce the risk of HIV infection. Clinical trials are underway to determine if pre-exposure prophylaxis (PrEP) is a safe and effective way to reduce HIV transmission in people at high risk for HIV infection.